Funding for this research was provided by:
Wellcome Trust (201406/Z/16/Z)
Oxford University | John Fell Fund, University of Oxford (0010945, COVID-19 Rebuilding Research Momentum)
CHILDREN with CANCER UK (16-224 - ’Children’s Brain Tumour Drug Delivery Consortium’)
Article History
Received: 3 December 2021
Revised: 26 January 2022
Accepted: 4 February 2022
First Online: 25 February 2022
Competing interests
: GH is currently the Chief Investigator on three trials related to radiotherapy, imaging and radiosensitisers. He also undertakes consultancy work and is a shareholder in Artios Pharma Ltd. No other disclosures are reported.
: Not applicable.
: Not applicable.